1. A portable surface air supply system, comprising:
a main cylinder frame having a plurality SCUBA cylinder nesting receptacles for having respective SCUBA cylinders received therein;
detachable umbilical tube baskets extending from respective opposite sides of said frame for carrying umbilical tubes therein; and
a dive control panel comprised of diver supply values, regulators, depth gauges and cross over valves connected for controlling air flow for respective divers, monitoring diver depth and crossing over to a new air supply in the event of failure of an air supply to a specific diver.
2. The system of claim 1, wherein said dive control panel further comprising life support gauges for monitoring diver physiological status and further comprising indicting gauges for indicating air supply status.
3. The system of claim 1, further comprising eight air cylinder pairs mounted on said frame, and umbilical tubes connectable to said air cylinder pairs for supplying air to at least one diver on a dive.
4. The system of claim 1, wherein said umbilical cord baskets are arranged for being connected to said frame to extend from the frame at respective outboard sides of a vessel.
5. The system of claim 1, wherein said main cylinder frame has outboard adjustable pontoon saddle arms having a cylindrical cross-section for being supported in a vessel having outboard pontoons to thereby be supported in the vessel on said pontoons.
6. The system of claim 1, wherein said main cylinder frame is adjustable in size for being adjusted to fit in a variety of different size vessels.
7. The system of claim 5, wherein said saddle arms are detachable from said main cylinder frame.
8. The system of claim 1, wherein said main cylinder frame comprises lifting points for connecting lifting lines thereto for allowing the main cylinder frame to be lifted as a whole.
9. The system of claim 5, further comprising four saddle arms.
10. The system of claim 9, wherein said saddle arms are adapted for having said umbilical tube brackets mounted thereon.
11. The system of claim 2, wherein said control panel further comprises indicators connectable to SCUBA cylinders for indicating cylinder pressure and air supply pressure.
12. The system of claim 3, wherein the control panel and umbilical tubes are configured for supplying air to two divers.
13. A method of conducting diving operations with the system of claim 1, comprising: providing (system)
connecting respective umbilical tubes to corresponding divers; and to twin SCUBA cylinders in the cylinder frame;
testing communication lines in the umbilical tubes open diver’s supply values on the dive control panel and check if value indications are acceptable for all cylinders; and
open driver supply values and commence diving operations.
14. The method of claim 13, further comprising switching a diver’s supply from one twin SCUBA cylinder to another twin SCUBA cylinder when the supply in the one twin SCUBA cylinder is being depleted.
15. The method of claim 14, further comprising conducting said switching when the one twin SCUBA cylinder has a pressure of about 300 to about 500 psi.
The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.
1. A compound represented by the following formula:
including both R and S enantiomeric forms, racemic mixtures, and pharmaceutically acceptable salts thereof; wherein:
R1 is one of the following:
each of which is substituted or unsubstituted;
R2 is selected from the group consisting of H and alkyl;
R3 is selected from the group consisting of H, alkyl, and substituted alkyl;
R4 is selected from the group consisting of halogen, \u2014SO2R4\u2033, \u2014SO2N(R4\u2032)2, \u2014OR4\u2033, \u2014N(R4\u2033)2, \u2014CON(R4\u2033)2, \u2014NHCOR4\u2033, \u2014NHSO2R4\u2033, alkyl, mono-substituted alkyl, di-substituted alkyl, and tri-substituted alkyl; wherein R4\u2032 is independently selected from the group consisting of halogen, alkyl, mono-substituted alkyl, di-substituted alkyl, and tri-substituted alkyl; and R4\u2033 is independently selected from the group consisting of halogen, hydrogen, alkyl, mono-substituted alkyl, di-substituted alkyl, tri-substituted alkyl, aryl, mono-substituted aryl, di-substituted aryl, tri-substituted aryl, cycloaliphatic, mono-substituted cycloaliphatic, di-substituted cycloaliphatic, and tri-substituted cycloaliphatic; and
R5 is selected from the group consisting of H and alkyl.
2. The compound of claim 1, wherein R1 is
which is substituted or unsubstituted.
3. The compound of claim 1, wherein R1 is
which is substituted or unsubstituted.
4. The compound of claim 1, wherein R1 is
which is substituted or unsubstituted.
5. The compound of claim 1, wherein R1 is
which is substituted or unsubstituted.
6. The compound of claim 1, wherein R3 is H or alkyl.
7. The compound of claim 1, wherein R4 is \u2014SO2R4\u2033 or \u2014SO2N(R4\u2032)2.
8. The compound of claim 1, wherein R4 is \u2014OR4\u2033.
9. The compound of claim 1, wherein R4 is \u2014N(R4\u2033)2 or \u2014CON(R4\u2033)2.
10. The compound of claim 1, wherein R4 is \u2014NHCOR4\u2033 or \u2014NHSO2R4\u2033.
11. The compound of claim 1, wherein R4\u2032 is alkyl; and R4\u2033 is independently hydrogen, alkyl, or aryl.
12. The compound of claim 7, wherein R4\u2032 is alkyl; and R4\u2033 is independently hydrogen, alkyl, or aryl.
13. The compound of claim 8, wherein R4\u2033 is hydrogen, alkyl, or aryl.
14. The compound of claim 9, wherein R4\u2033 is independently hydrogen, alkyl, or aryl.
15. The compound of claim 10, wherein R4\u2033 is independently hydrogen, alkyl, or aryl.
16. The compound of claim 1, wherein R1 is
R3 is H or alkyl; and R4 is \u2014SO2R4\u2033, \u2014SO2N(R4\u2032)2, or \u2014OR4\u2033.
17. The compound of claim 1, wherein R1 is
R3 is H or alkyl; and R4 is \u2014N(R4\u2033)2, \u2014CON(R4\u2033)2, \u2014NHCOR4\u2033, or \u2014NHSO2R4\u2033.
18. The compound of claim 1, wherein the compound is one of the following:
or a pharmaceutically acceptable salt thereof.
19. A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.
20. A method of treating a disorder selected from the group consisting of graft-versus-host disease, rheumatoid arthritis, Sjogren’s syndrome, myasthenia gravis, asthma, psoriasis, cancer, systemic lupus erythematosus, multiple sclerosis, Celiac Sprue, idiopathic thrombocytopenia purpura, scleroderma, Crohn’s Disease, inflammatory bowel disease, and ulcerative colitis, comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to a patient in need thereof to treat the disorder.